Autolus Therapeutics AUTL
NASDAQ AUTL
$1.32 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Autolus Therapeutics (AUTL) Current Deferred Revenue (2025)

Updated

Autolus Therapeutics (AUTL) recorded Current Deferred Revenue of $7.61 million in Q3 2025, up 262.5% from the prior quarter.

Analysis

Autolus Therapeutics (AUTL) Current Deferred Revenue (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Autolus Therapeutics 328.71 Mn -770.49 Mn 25.22 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 7.61 Mn
Jun 30, 2025 2.10 Mn
Mar 31, 2025 4.73 Mn
API Access

Autolus Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AUTL&period=max&api_key=YOUR_API_KEY